Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Optimized Treatment and Regression of HBV-induced Liver Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01938781
Recruitment Status : Completed
First Posted : September 10, 2013
Last Update Posted : July 27, 2018
Sponsor:
Collaborators:
Peking University People's Hospital
RenJi Hospital
Peking University
Shanghai Zhongshan Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Public Health Clinical Center
Nanfang Hospital of Southern Medical University
Sir Run Run Shaw Hospital
Beijing YouAn Hospital
Peking University First Hospital
Beijing 302 Hospital
Peking Union Medical College Hospital
Beijing Ditan Hospital
Beijing Tiantan Hospital
Huashan Hospital
Tongji Hospital
Tang-Du Hospital
Fifth Hospital of Shijiazhuang City
Logistics University of Chinese People's Armed Police Forces
The First Affiliated Hospital of Shanxi Medical University
The Affiliated Hospital of Yanbian University
Information provided by (Responsible Party):
Hong You, Beijing Friendship Hospital

Brief Summary:
Patients with chronic hepatitis B histologically confirmed of liver fibrosis S2/S3 (similar to metavir F2/F3, Ishak 2/3/4) are randomly assigned in a 1:1 ratio. One arm is entecavir alone for 2 years; the other is entecavir alone for the first 0.5 year, entecavir plus pegylated interferon (peg-IFN) for 1 year, entecavir for another additional 0.5 year. Patients will be assessed at baseline, at every six months for blood count, liver function test, HBVDNA, AFP, prothrombin time, thyroid function, liver ultrasonography, and Fibroscan. The second liver biopsy will be performed to evaluate regression rate of liver fibrosis 1.5 years after initial therapy.

Condition or disease Intervention/treatment Phase
Liver Fibrosis Drug: entecavir Drug: Peg-IFN Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Optimized Treatment and Regression of HBV-induced Liver Fibrosis
Study Start Date : June 2013
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Entecavir

Arm Intervention/treatment
Active Comparator: Entecavir monotherapy
entecavir, 0.5mg, qd, oral, for 2 years.
Drug: entecavir
antiviral therapy
Other Name: entecavir dispersible tablets

Experimental: Entecavir plus peg-IFN Therapy
entecavir combined peg-IFN in the middle 1 year.
Drug: entecavir
antiviral therapy
Other Name: entecavir dispersible tablets

Drug: Peg-IFN
antiviral and antifibrosis therapy
Other Name: Pegasys




Primary Outcome Measures :
  1. Regression Rate of HBV-induced Liver Fibrosis [ Time Frame: 1.5 to 2 years ]
    Fibrosis regression of 1 point by Ishak scoring system


Secondary Outcome Measures :
  1. HBVDNA undetectable rate [ Time Frame: 1 year and 2 years ]
    The HBVDNA undetectable rate after 1 year and 2-year treatment

  2. Fibroscan scores [ Time Frame: 1 year and 2 years ]
    Fibroscan scores after 1 and 2-year treatment

  3. Life Quality [ Time Frame: 1 year and 2 years ]
    Life quality after 1 and 2-year treatment by SF-36 and EQ-5D questionaire

  4. Incidence of drug resistance [ Time Frame: 1 year and 2 years ]
    Incidence of drug resistance after 1 and 2-year treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Ages from 18 to 65 years old;
  2. Male or female;
  3. Treatment-naive patients with chronic HBV-induced fibrosis S2/S3 (similar to F2/F3, Ishak 2/3/4), who consent to undergo liver biopsy before and after treatment;
  4. Patients with HBeAg-positive, HBVDNA>2×10<4> IU/ml or with HBeAg-negative, HBVDNA>2×10<3> IU/ml;
  5. Agree to be follow-up regularly;
  6. signature of written inform consent.

Exclusion Criteria:

  1. Patients with decompensated cirrhosis: including ascites, hepatic encephalopathy, esophageal varices bleeding or other complications of decompensated cirrhosis or hepatocelluar carcinoma;
  2. Patients who are allergic to entecavir, interferon, or their components, and those considered not suitable for medications used in this study;
  3. Patients coinfection with HCV or HIV, alcoholic liver disease, autoimmune liver disease, genetic liver disease, drug-induced liver injury, severe non-alcoholic fatty liver disease or other chronic liver diseases;
  4. Patients with baseline AFP level higher than 100 ng/ml and possible malignant lesion on image, or AFP level higher than 100 ng/ml for continuous three months;
  5. Creatinine >1.5×ULN;
  6. Patients with other uncured malignant tumors;
  7. Patients with severe diseases of heart, lung, kidney, brain, blood system or other organs;
  8. Patients with severe neurological or psychological disease (e.g. epilepsy, depression, mania and schizophrenia);
  9. Patients with poorly controlled diabetes, hypertension or thyroid disease;
  10. Patients with any other reasons not suitable for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01938781


Locations
Layout table for location information
China, Beijing
Beijing Ditan Hospital, Capital Medical University
Beijing, Beijing, China, 100015
Peking University First Hospital
Beijing, Beijing, China, 100034
Peking University People's Hospital
Beijing, Beijing, China, 100034
302 Military Hospital Of China
Beijing, Beijing, China, 100039
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing, China, 100050
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing, China, 100050
Beijing YouAn Hospital, Capital Medical University
Beijing, Beijing, China, 100069
Peking Union Medical College Hospital
Beijing, Beijing, China, 100730
Peking Uiversity
Beijing, Beijing, China, 100871
China, Guangdong
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515
China, Hebei
Shijiazhuang Fifth Hospital
Shijiazhuang, Hebei, China, 050021
China, Hubei
Tongji Hospital, Tongji Medical College, Huazhong University of Science &Technology
Wuhan, Hubei, China, 300030
China, Jilin
The Affiliated Hospital of Yanbian University
Yanji, Jilin, China, 133000
China, Shanghai
Renji Hospital, Shanghai Jiao Tong University, School of Medicine
Shanghai, Shanghai, China, 200032
Huashan Hospital FuDan University
Shanghai, Shanghai, China, 200040
Zhongshan Hospital Fudan University
Shanghai, Shanghai, China, 200040
Shanghai First People's Hospital
Shanghai, Shanghai, China, 200080
Shanghai Public Health Clinical Center
Shanghai, Shanghai, China, 201508
China, Shanxi
The First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China, 030001
China, Tianjin
The Hospital Affiliated to Logistics University of Chinese People's Armed Police Force
Tianjin, Tianjin, China, 300162
China, Zhejiang
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China, 310016
Sponsors and Collaborators
Beijing Friendship Hospital
Peking University People's Hospital
RenJi Hospital
Peking University
Shanghai Zhongshan Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Public Health Clinical Center
Nanfang Hospital of Southern Medical University
Sir Run Run Shaw Hospital
Beijing YouAn Hospital
Peking University First Hospital
Beijing 302 Hospital
Peking Union Medical College Hospital
Beijing Ditan Hospital
Beijing Tiantan Hospital
Huashan Hospital
Tongji Hospital
Tang-Du Hospital
Fifth Hospital of Shijiazhuang City
Logistics University of Chinese People's Armed Police Forces
The First Affiliated Hospital of Shanxi Medical University
The Affiliated Hospital of Yanbian University
Investigators
Layout table for investigator information
Principal Investigator: Hong You, Doctor Beijing Friendship Hospital

Layout table for additonal information
Responsible Party: Hong You, Vice-Director of Liver Research Center, Beijing Friendship Hospital
ClinicalTrials.gov Identifier: NCT01938781     History of Changes
Other Study ID Numbers: 2013ZX10002004-1
First Posted: September 10, 2013    Key Record Dates
Last Update Posted: July 27, 2018
Last Verified: July 2018

Keywords provided by Hong You, Beijing Friendship Hospital:
Hepatitis B
Liver fibrosis
Regression
Efficacy

Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Cirrhosis
Fibrosis
Pathologic Processes
Liver Diseases
Digestive System Diseases
Entecavir
Antiviral Agents
Anti-Infective Agents